未找到相关数据
Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL)
被引：0
作者：
Brummendorf, T. H.
Cortes, J. E.
Kantarjian, H.
Gambacorti-Passerini, C.
Baccarani, M.
Kim, D.
Zaritskey, A.
Navarro, J.
Rapoport, A.
Dorlhiac-Llacer, P. E.
Milone, J.
Zanichelli, M.
Besson, N.
Leip, E.
Kelly, V.
Khoury, H. J.
机构：
[1] Rhein Westfal TH Aachen, Univ Klinikum Hamburg Eppendorf, Univ Klinikum Aachen, Aachen, Germany
[2] RWTH, Univ Klinikum Hamburg Eppendorf, Univ Klinikum Aachen, Hamburg, Germany
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Milano Bicocca, Monza, Italy
[5] Univ Bologna, Bologna, Italy
[6] Seoul St Marys Hosp, Seoul, South Korea
[7] Univ Pavlov, St Petersburg, Russia
[8] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru
[9] Greenebaum Canc Ctr, Baltimore, MD USA
[10] FMUSP, Hosp Clin, Sao Paulo, Brazil
[11] Inst Trasplante Medula Osea, La Plata, Buenos Aires, Argentina
[12] Univ Sao Paulo, Childrens Inst, Sao Paulo, Brazil
[13] Pfizer Global Res & Dev, Paris, France
[14] Pfizer Inc, Cambridge, MA USA
[15] Emory Univ, Sch Med, Atlanta, GA USA
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.6535
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6535
引用
收藏
页数：1
相关论文